Scarica l'app Stockscreener
149.33
0.45%
-0.67
Dopo l'orario di chiusura:
149.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Insmed Inc Borsa (INSM) Ultime notizie
Insmed, Inc. Experiences Revision in Its Stock Evaluation Amid Financial Performance Trends - Markets Mojo
Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In - Finviz
Westfield Capital Management Co. LP Lowers Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Thornburg Investment Management Inc. Trims Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Stock Hits Day Low of $148.24 Amid Price Pressure - Markets Mojo
Insmed (INSM) Q4 2025 Earnings Call Transcript - AOL.com
HC Wainwright Forecasts Insmed's Q3 Earnings (NASDAQ:INSM) - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
H.C. Wainwright Remains a Buy on Insmed (INSM) - The Globe and Mail
INSM Stock Rating: Mizuho Lowers Price Target Amid Consistent Ou - GuruFocus
Mizuho Issues Pessimistic Forecast for Insmed (NASDAQ:INSM) Stock Price - MarketBeat
Insmed Incorporated (INSM) Gained from Its Lead Product ARIKAYCE - Yahoo Finance
HC Wainwright Comments on Insmed's Q1 Earnings (NASDAQ:INSM) - MarketBeat
Insmed chair and CEO Lewis sells $1.6m in stock - Investing.com
Insmed (INSM) Is Up 6.9% After BRINSUPRI Sales Beat Expectations And 2026 Target SetWhat's Changed - Yahoo Finance
H.C. Wainwright reiterates Buy on Insmed stock, $230 target By Investing.com - Investing.com UK
William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
INSM: HC Wainwright & Co. Reiterates Buy Rating with $230 PT | I - GuruFocus
Mizuho Securities Cuts Insmed Price Target to $204 From $211, Maintains Outperform Rating - marketscreener.com
Insmed (NASDAQ:INSM) Given Buy Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy on Insmed stock, $230 target - Investing.com
Patient Square Capital LP Reduces Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Gets UK Marketing Authorization for Non-Cystic Fibrosis Bronchiectasis Treatment - marketscreener.com
Hillsdale Investment Management Inc. Sells 7,000 Shares of Insmed, Inc. $INSM - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Insmed (INSM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and Insmed (INSM) - The Globe and Mail
Wells Fargo Lowers Price Target for Insmed (INSM) Amid Overweigh - GuruFocus
Breaking Down Insmed: 16 Analysts Share Their Views - Benzinga
Wall Street Analysts Think Insmed (INSM) Could Surge 33.6%: Read This Before Placing a Bet - Finviz
Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View - Bitget
Insmed Q4 Reinforces Confidence in Brinsupri Growth, RBC Says - marketscreener.com
Insmed May Top Revenue Target for Bronchiectasis Drug Brinsupri, Morgan Stanley Says - marketscreener.com
Insmed Incorporated (NASDAQ:INSM) Q4 2025 Earnings Call Transcript - Insider Monkey
Skandinaviska Enskilda Banken AB publ Grows Position in Insmed, Inc. $INSM - MarketBeat
Morgan Stanley Lifts Price Target on Insmed to $166 From $162, Keeps Equalweight Rating - marketscreener.com
Insmed, Inc. $INSM Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
Fiera Capital Corp Grows Stock Position in Insmed, Inc. $INSM - Defense World
Insmed (INSM) Poised for 2026 Upside With Potential $1.3B Arikayce Sales Boost, Roth/MKM Initiates Buy - Finviz
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed: Q4 Earnings Snapshot - theheraldreview.com
Insmed jumps as new drug launch momentum drives bullish 2026 revenue outlook - Quiver Quantitative
Insmed Inc (INSM) Q4 2025 Earnings Call Highlights: Strong Brin Suri Launch and Promising 2026 ... By GuruFocus - Investing.com Canada
A Closer Look at Insmed's Options Market Dynamics - Benzinga
Insmed Inc (INSM) Q4 2025 Earnings Call Highlights: Strong Brin Suri Launch and Promising 2026 Revenue Outlook - GuruFocus
Insmed (INSM) Projects Significant Revenue Growth with BRINSUPRI's Success - GuruFocus
Insmed (NASDAQ:INSM) Issues Earnings Results - MarketBeat
Insmed Incorporated Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Insmed Q4 2025 misses EPS, beats revenue By Investing.com - Investing.com UK
Insmed Q4 Earnings Call Highlights - Yahoo Finance
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Earnings call transcript: Insmed Q4 2025 misses EPS, beats revenue - Investing.com
Insmed Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Mcrae Capital Management Inc. Invests $3.92 Million in Insmed, Inc. $INSM - MarketBeat
Insmed (INSM) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Insmed reports fourth-quarter and full-year 2025 financial results and provides business update - marketscreener.com
1.67%
1.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):